RA Capital Management 13F holdings, Q4 2007
Holdings as of December 31, 2007 · filings on SEC EDGAR · latest filing →
RA Capital Management disclosed 23 US equity positions worth $158.7m in its Q4 2007 13F filing. The largest position was POZEN INC at 10.2% of the reported book, followed by QUESTCOR PHARMACEUTICALS INC and ADOLOR CORP.
What did RA Capital Management own in Q4 2007? Top 23 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs prior |
|---|---|---|---|---|---|---|---|
| 1 | POZEN INC | 10.2% | $16.2m | 1,351,922 | – | ||
| 2 | QUESTCOR PHARMACEUTICALS INC | 9.2% | $14.5m | 2,520,691 | – | ||
| 3 | ADOLOR CORP | 8.9% | $14.2m | 3,078,872 | – | ||
| 4 | OREXIGEN THERAPEUTICS INC | 7.3% | $11.6m | 816,781 | – | ||
| 5 | NBIX NEUROCRINE BIOSCIENCES INC | Healthcare | 6.9% | $10.9m | 2,405,000 | – | |
| 6 | ROCKWELL MEDICAL TECH | 6.2% | $9.8m | 1,366,667 | – | ||
| 7 | OMRIX BIOPHARMACEUTICALS INC | 5.8% | $9.2m | 263,761 | – | ||
| 8 | CRIS CURIS INC | 4.7% | $7.4m | 7,550,564 | – | ||
| 9 | CYTOKINETICS INC | 4.2% | $6.7m | 1,424,232 | – | ||
| 10 | JAVELIN PHARMACEUTICALS INC | 4.2% | $6.6m | 1,773,929 | – | ||
| 11 | ATHERSYS INC | 3.9% | $6.1m | 1,245,976 | – | ||
| 12 | KERYX BIOPHARMACEUTICALS INC | 3.4% | $5.4m | 639,391 | – | ||
| 13 | COUGAR BIOTECHNOLOGY INC | 3.3% | $5.2m | 159,873 | – | ||
| 14 | TRANSITION THERAPEUTICS INC | 3.0% | $4.8m | 423,951 | – | ||
| 15 | ARDEA BIOSCIENCES INC | 2.9% | $4.6m | 301,887 | – | ||
| 16 | RIGL RIGEL PHARMACEUTICALS INC | Healthcare | 2.5% | $4.0m | 158,698 | – | |
| 17 | CHELSEA THERAPEUTICS INTL LT | 2.4% | $3.8m | 512,612 | – | ||
| 18 | SUPERGEN INC | 2.3% | $3.7m | 1,008,132 | – | ||
| 19 | LIPID SCIENCES INC ARIZ | 2.1% | $3.3m | 3,713,962 | – | ||
| 20 | VNDA VANDA PHARMACEUTICALS INC | Healthcare | 2.0% | $3.1m | 450,000 | – | |
| 21 | REPROS THERAPEUTICS INC | 1.7% | $2.8m | 297,362 | – | ||
| 22 | ISTA PHARMACEUTICALS INC | 1.7% | $2.7m | 552,999 | – | ||
| 23 | TRUBION PHARMACEUTICALS INC | 1.2% | $1.9m | 193,732 | – |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.